01:23 AM EDT, 10/06/2026 (MT Newswires) -- Formycon (FYB.F) is expanding its use of artificial intelligence and other digital technologies to improve the efficiency of biosimilar development under its FYB4GROWTH strategy. The German biosimilar developer said Tuesday it is introducing Phlexglobal's artificial intelligence-supported electronic trial master file platform as a central system for current and future clinical development activities. Formycon has also deployed AI-based software to analyze manufacturing process data to boost collaboration with contract manufacturers and support assessments of critical quality attributes.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.